Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 in Mesalamine-Refractory Ulcerative Colitis
NCT02142725Phase 3Terminated
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jul 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of phosphatidylcholine in ulcerative colitis (UC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of clinical remission at 12 weeks. Started Jul 2014; status: terminated.
02
Drugs
phosphatidylcholine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02142725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02142725.